| P50 | author | Francesco Menzella | Q83419749 |
| P2093 | author name string | Marco Caminati | |
| | Gianenrico Senna | |
| | Lucia Guidolin | |
| P2860 | cites work | Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common beta-chain bound to an antagonist | Q27622116 |
| | A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5 | Q27732152 |
| | Innate lymphoid cells in allergic and nonallergic inflammation | Q28080217 |
| | Reslizumab for Poorly Controlled, Eosinophilic Asthma | Q29040017 |
| | Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia | Q34230967 |
| | Hypereosinophilic Syndrome | Q34498306 |
| | Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma | Q34557028 |
| | European Position Paper on Rhinosinusitis and Nasal Polyps 2012. | Q34640008 |
| | Treatment of patients with the hypereosinophilic syndrome with mepolizumab | Q34762186 |
| | Biologic therapies targeting eosinophils: current status and future prospects | Q35565533 |
| | Severe refractory asthma: current treatment options and ongoing research | Q59792091 |
| | Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: Case report and review of the literature | Q59812079 |
| | MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function | Q60632052 |
| | Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases | Q61446618 |
| | Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial | Q61959735 |
| | Prevalence of severe asthma according to the drug regulatory agency perspective: An Italian experience | Q64059378 |
| | Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. | Q64982028 |
| | Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro | Q67930606 |
| | Sustained response to mepolizumab in refractory Churg-Strauss syndrome | Q82680787 |
| | Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome | Q84332714 |
| | Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome | Q84893066 |
| | Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab | Q88389813 |
| | Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review | Q88687918 |
| | Emerging drugs for eosinophilic esophagitis | Q88921874 |
| | Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis | Q89456551 |
| | Allergic bronchopulmonary aspergillosis successfully treated with benralizumab | Q90249972 |
| | Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab | Q90714780 |
| | Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps | Q90761262 |
| | Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab | Q91295885 |
| | Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps | Q91334784 |
| | How Important Is Adherence to Inhaled Medications Before Starting a Biologic Therapy for Asthma? | Q91345314 |
| | A case of chronic eosinophilic pneumonia successfully treated with mepolizumab | Q91366159 |
| | Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison | Q91386556 |
| | Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial | Q92985120 |
| | Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics | Q36001230 |
| | Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma | Q36654007 |
| | The consequences of not having eosinophils. | Q37561562 |
| | Eosinophilic esophagitis: updated consensus recommendations for children and adults | Q37863307 |
| | Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study | Q38388496 |
| | Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis | Q38780534 |
| | Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. | Q38843805 |
| | Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis | Q39030902 |
| | Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature. | Q39043486 |
| | Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Q39408906 |
| | Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. | Q39627826 |
| | Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies | Q39768068 |
| | Pathophysiology of Eosinophilic Esophagitis | Q40114032 |
| | Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity | Q40924236 |
| | Interleukin-5 and human B lymphocytes | Q41302809 |
| | Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials | Q41452053 |
| | Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors | Q41690137 |
| | Hemopoietic progenitors: the role of eosinophil/basophil progenitors in allergic airway inflammation | Q43061567 |
| | Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese | Q44931461 |
| | Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Q45297326 |
| | Purification and partial sequence analysis of murine B cell growth factor II (interleukin 5). | Q45966527 |
| | Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab | Q47187666 |
| | Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial | Q47249808 |
| | Safety and Efficacy of Reslizumab for Children and Adolescents With Eosinophilic Esophagitis Treated Over Nine Years | Q47412418 |
| | Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma | Q47713436 |
| | Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial | Q47840140 |
| | Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics | Q47963812 |
| | Mepolizumab treatment in patients with severe eosinophilic asthma | Q48065984 |
| | Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial | Q48509747 |
| | Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis | Q49046464 |
| | Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps | Q49069941 |
| | Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma | Q49572572 |
| | Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. | Q51026334 |
| | Eosinophilic Lung Diseases. | Q51472283 |
| | Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. | Q51563764 |
| | Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. | Q51699006 |
| | A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. | Q52340148 |
| | An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. | Q53226482 |
| | Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. | Q53583932 |
| | Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. | Q53850475 |
| | Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. | Q55034563 |
| | Eosinophils from Physiology to Disease: A Comprehensive Review. | Q55311740 |
| | Type 2 immunity in asthma. | Q55454410 |
| | Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives | Q57179402 |
| | Matching-Adjusted Indirect Comparison of Benralizumab Interleukin-5 Inhibitors: Systematic Review | Q57475877 |
| | Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma | Q57803338 |
| | Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma | Q58723876 |
| | Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab | Q59329818 |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 212587 | |
| P577 | publication date | 2019-07-23 | |
| P1433 | published in | Drugs in context | Q26842115 |
| P1476 | title | Targeting eosinophils: severe asthma and beyond | |
| P478 | volume | 8 | |